A challenging case: how should an IRB rule when a protocol calls for using an extremely vulnerable population: the dying?
Agich
George
G
Cleveland Clinic, Lerner College of Medicine, Case Western Reserve University, OH, USA.
Smith
David
D
Levine
Robert
R
D016915:AIDS Vaccines; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D017321:Clinical Trials, Phase I as Topic / Q000941:ethics; D028744:Ethics Committees, Research; D006805:Human Experimentation / Q000941:ethics*; D006801:Humans; D007258:Informed Consent / Q000941:ethics; D035842:Research Subjects; D019452:Terminally Ill; D035862:Vulnerable Populations
D016915:AIDS Vaccines